New information about Von Willebrand's factor?

HealthMED

Volumn 4, Issue 1, 2010, Pages 187-194

  Babic, Nermina ^a   Huskic, Jasminko ^a   Nakas Icindic, Emina ^a   Tihic Kapidzic, Suzana ^a   Music, Miralem ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

Endothelial dysfunction; Multimers; Platelets; Von Willebrand factor (vWf)

Indexed keywords

EID: 77949461841     PISSN: 18402291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990;6:217-46.
2. Andrews RK, Berndt MC. Platelet adhesion: A game of catch and release. J Clin Invest 2008; 118(9): 3009-11.
3. Girma JP. Biology of von Willebrand factor. Nephrol Ther. 2006 Jan;2 Suppl 2:143-8.
4. Shapiro J, Sclaky N, Lee J, Bosshart H Angeletti RH, Bonifacino JS. Localization of endogenous furin in cultured cell lines. J Histochem Cytochem 1997;45:3-12.
5. Haberichter SL, Scot AF, Montgomery RR. Von Willebrand factor storage and multimerization: 2 independent intracellular processes. Blood 2000;96:1808-15.
6. Vischer UM, Wagner DD. Von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 1994;83:3536-44.
7. Michaux G, Abbitt KB, Collinson LM, Haberichter SL, Norman KE, Cutler DF. The physiological function of von Willebrand's factor depends on its tubular storage in endothelial Weibel-Palade bodies. Dev Cell 2006;10(2):223-32.
8. Mourik JA van, Romani de Wit T, Voorberg J. Biogenesis and exocytosis of Weibel-Palade bodies. Histochem Cell Biol 2002;117:113-22.
9. Borchiellini A, Fijnvandraat K, JW ten Cate, Pajkrt D, SJ van Deventer, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, JA van Mourik. Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996;88(8):2951-8.
10. Lip GYH, Blann A. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovascular research 1997;34:255-65.
11. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005;3:1710-6.
12. Vischer UM, Barth H, Wollheim CB. Regulated von Willebrand factor secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells . Arterioscler Thromb Vasc Biol. 2000;20:883-91.
13. Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood 2008;112(4):957-64.
14. Johnsen J, López JA. vWf secretion: what's in a name?. Blood 2008;112(4):926-7.
15. Andrews RK, Berndt MC. Platelet adhesion: a game of catch and release. J Clin Invest 2008;118(9):3009-11.
16. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost. 2003;1(7):1335-42.
17. Ruggeri ZM. Von Willebrand factor: Looking back and looking forward. Thromb Haemost 2007;98:55-62.
18. Nichols T, Samama C, Bellinger D, Roussi J, Reddick R, , Bonneau M. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc Natl Acad Sci USA 1995;92:2455-9.
19. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD: von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002;23:1764-70.
20. Franchini M, Lippi G: von Willebrand factor and thrombosis. Ann Hematol 2006;85:415-23.
21. Keuren JFW , Baruch D, Legendre P, Denis CV, Lenting PJ, Girma JP, Lindhout T. Von Willebrand factor C1C2 domain is involved in platelet adhesion to polymerized fibrin at high shear rate. Blood 2004;103:1741-6.
22. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, Mcintre LV, Fujikawa K, Lopez JA. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002;100:4033-9.
23. Kumari M, Marmot M, Brunner E. Social determinants of von Willebrand factor The Whitehall II study. Arteroscler Thromb Vasc Biol. 2000;20:1842-7.
24. Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thrombosis Journal 2007;5:14-8.
25. Ordulu E, Erdogan O. Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes. Int J Card 2008;128(2):282-4.
26. Fish RJ, Yang H, Viglino CH, Schorer R, Dunoyer-Geindre S, Kruithof EKO. Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues. Biochem J. 2007 August 1; 405(Pt 3): 597-604.
27. Damin DC, Rosito MA, Gus P, Roisemberg I, Bandinelli E, Schwartsmann G. Von Willebrand factor in colorectal cancer. Int J Colorectal Dis. 2002 Jan;17(1):42-5.
28. Boneu B, Abbal M, Plante J, Bierme R. Factor VIII complex and endothelial damage. Lancet 1975;1:1430
29. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006;368:33-47.
30. Kiki I, Köse N, Gündoǧdu M, Kaya H, Çetinkaya R. Relationship between von Willebrand factor activity and therapeutic success of thrombolytic therapy in patients with myocardial infarction.Eur J Gen Med 2007;4(2):57-61.
31. Horvath B, Hegedus D, Szapary L, Marton Z, Alexy T, Koltai K, Gyevnar Z, Juricskay I, Toth K, Kesmarky G. Investigation of von Willebrand factor as a marker of endothelial dysfunction in atherosclerotic patients. Orvosi hetilap 2003;144(50):2471-6.
32. Hirano T, Ookubo K, Kashiwazaki K, Tajima H, Yoshino G, Adachi M. Vascular endothelial markers, von Willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease. Clinica chimica acta 2000;299(1-2):65-75.
33. Chan NN, Fuller JH, Rubens M, Colhoun HM. Von Willebrand factor in type 1 diabetes: its relationship with endothelial nitric oxide production and coronary artery calcification. Med Sci Monit 2003;9(7)297-303.
34. Ibrahim HA, El-Meligi AA, Abdel-Hamid M, Elhendy A. Relations between von Willebrand factor, markers of oxidative stress and microalbuminuria in patients with type 2 diabetes mellitus. Med Sci Monit 2004;10(3):85-9.
35. Gosk-Bierska I, Adamiec R, Alexewicz P, Wysokinski WE. Coagulation in diabetic and non-diabetic claudicants. Int Angiol 2002 Jun;21(2):128-33.
36. Dejanov P, Polenaković M, Oncevski A, Sikole A, Dejanova B, Panov S, Kostovska S. The role of the von Willebrand factor in renal diseases and haemodialysis patients. Prilozi. 2004;25(1-2):5-15.
37. Lu GY, Shen L, Wang ZY, Guo XF, Bai X, Su J, Ruan CG. Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases. Chin Med J (Engl). 2008 Jan 20;121(2):133-6.
38. Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost. 2006; 4: 2490-3.
39. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006;4:1186-93.
40. Yoo G, Blombäck M, Schenck-Gustafsson K, He S. Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation. Br J Haematol 2003;121:123-9.